바로팜 KRX:0153R0KOSDAQ
바로팜 · Korean news coverage and regulatory filings, organized.
In Q3 2026, 바로팜 reported revenue of ₩49.6bn, up 77.9% year on year, and operating profit of ₩2.3bn. 바로팜 (바로팜) appeared in 12 Korean news articles and 3 DART filings over the past seven days. Coverage peaked on Nov 16 with 6 articles. It was most often mentioned alongside GC Genome.
Filing signals Turnaround Revenue +30% Screener
바로팜 today: up or down?
No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.
Upcoming dates as filed
- Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026
Dates 바로팜 stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.
바로팜 quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q3 2026 | ₩49.6bn | +77.9% | ₩2.3bn margin 4.7% | ₩2.1bn |
| Q3 2025 | ₩27.8bn | – | −₩177m margin −0.6% | −₩1.6bn |
바로팜 ranks #866 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
바로팜 top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest 바로팜 news Korean headlines
-
Baropharm Revicle enters 350 Cosmemed stores in Taiwan
2 more on this story · 2 outlets
- Baropharm Rebicle confirmed for 350 stores at Taiwan Cosmeds메디파나뉴스 · Nov 13 10:22
- Baropharm's Levicle confirmed for entry into 350 Cosmed outlets in Taiwan보건신문 · Nov 13 12:16